ClinicalTrials.gg
CompletedNCT00077779CHARMUpdated Sep 26, 2007

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

A Phase 3 interventional study of Adalimumab in Crohn's Disease, sponsored by Abbott. Completed at 43 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-09-26.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
854
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
3rd of 42
854 · median 143
Started
2003
the only one that year
Phase 3
22 of 42
none open now
Registered
3rd of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 3rd largest by enrollment, is the only one that started in 2003, is one of 22 in phase 3, and was the 3rd registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between the ages of 18 and 75 who are diagnosed with moderate to severe Crohn's Disease defined by a CDAI score of >= 220 and \<= 450, normal laboratory parameters,
  • are willing and able to give , and
  • are able to self-inject or have a designee or healthcare professional who can inject the study medication.

Exclusion criteria

Exclusion:

  • History of certain types of cancer, diagnosis of ulcerative colitis,
  • female or breast feeding subjects,
  • surgical bowel resection(s) with in the past 6 months,
  • history of listeria,
  • (HIV),
  • central nervous system demyelinating disease or untreated TB,
  • history of a poorly controlled medical condition,
  • unsuccessful response to infliximab or any anti-TNF agent use in the past.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
854 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical remission (CDAI<150).

    Time frame: 56 weeks

07

Study locations

43 sites
  • Thornton Hospital Reumatology Division
    La Jolla, California 92037-0943, United States
  • UCSF San Francisco General Hospital
    San Francisco, California 94110, United States
  • Cal-West, Inc.
    San Francisco, California 94117, United States
  • Western States Clinical Research
    Arvada, Colorado 80002, United States
  • Gastroenterology Associates of Fairfield County
    Bridgeport, Connecticut 06606, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • V.A. Medical Center
    Gainsville, Florida 32608, United States
  • Mark Lamet, MD
    Hollywood, Florida 33021, United States
  • Gastroenterology Consultants
    Ormond Beach, Florida 32174, United States
  • Northwest Gastroenterology
    Arlington Heights, Illinois 60005, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Indianapolis Gastroenterology Research Foundation
    Indianapolis, Indiana 46237, United States
  • St. Vincent Hospital: Research Department
    Indianapolis, Indiana 46260, United States
  • Drug Research Services, Inc.
    Metairie, Louisiana 70001, United States
  • Maryland Clinical Trials
    Annapolis, Maryland 21401, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Capital Gastroenterology Consultants, P.A.
    Silver Spring, Maryland 20901, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Mayo Clinic Research
    Rochester, Minnesota 55905-0002, United States
  • Gastroenterology & Hematology
    Kansas City, Missouri 64131, United States
  • Glenn Gordon, MD
    Mexico, Missouri 65265, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Washington University School
    St. Louis, Missouri 63110, United States
  • Long Island Clinical Research Assoc.
    Great Neck, New York 11021, United States
  • NY Center for Clinical Research
    Lake Success, New York 11042, United States
  • Daniel Present, MD
    New York, New York 10029, United States
  • Digestive Disease Associates of Rockland
    Pomona, New York 10970, United States
  • Charlotte Gastroenterology & Hepatology
    Charlotte, North Carolina 28207, United States
  • Carolina Digestive Health Associates
    Charlotte, North Carolina 28211, United States
  • Carolina Research Associates
    Charlotte, North Carolina 28262, United States
  • Le Bauer Research, P.A.
    Greensboro, North Carolina 27403, United States
  • Wilmington Gastroenterology
    Wilmington, North Carolina 28401, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Westhills Gastroenterology
    Portland, Oregon 98112, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15261, United States
  • Columbia Gastro Associates
    Columbia, South Carolina 29204, United States
  • Gastroenterology Center of the Mid South
    Memphis, Tennessee 38120, United States
  • Nashville Medical Research
    Nashville, Tennessee 37205, United States
  • Gastrointestinal Specialists
    Richmond, Virginia 23230, United States
  • Discovery Research Inteternational, LLC
    Milwaukee, Wisconsin 53215, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53215, United States
08

References and documents

Publications

  • Sandborn WJ, Lewis JD, Panes J, Loftus EV, D'Haens G, Yu Z, Huang B, Lacerda AP, Pangan AL, Feagan BG. Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease. J Crohns Colitis. 2022 Mar 14;16(3):444-451. doi: 10.1093/ecco-jcc/jjab161. PubMed 34546360 ↗
  • Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6. PubMed 29380251 ↗
  • Panaccione R, Colombel JF, Sandborn WJ, D'Haens G, Zhou Q, Pollack PF, Thakkar RB, Robinson AM. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013 Nov;38(10):1236-47. doi: 10.1111/apt.12499. Epub 2013 Sep 22. PubMed 24134498 ↗
  • Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013 Apr;7(3):213-21. doi: 10.1016/j.crohns.2012.05.015. Epub 2012 Jun 16. PubMed 22704916 ↗
  • Kamm MA, Hanauer SB, Panaccione R, Colombel JF, Sandborn WJ, Pollack PF, Zhou Q, Robinson AM. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug;34(3):306-17. doi: 10.1111/j.1365-2036.2011.04717.x. Epub 2011 Jun 5. PubMed 21645018 ↗
  • Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009 Jul;58(7):940-8. doi: 10.1136/gut.2008.159251. Epub 2009 Feb 6. PubMed 19201775 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 26, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00077779
Lead sponsor
Abbott
First posted
Feb 16, 2004
Start date
Jul 2003
Last update
Sep 26, 2007

Study contacts

Paul F Pollack, M.D.
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion